No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case‐control study.

No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. During a total follow-up of 31 448 patient-years, 573 patients had a surgery for cataract and 1089 (12-9%) were exposed to eltrombopag (309 with >=365 DDDs). II TableRisk of cataract surgery associated with exposure to eltrombopag in patients with immune thrombocytopenia (ITP). (2017) Occurrence and management of cataracts in adult patients (pts) with chronic immune thrombocytopenia (cITP) during long-term treatment with eltrombopag (EPAG): Results from the extend study. [Extracted from the article]